Collegium Pharmaceutical reported second-quarter 2026 results with product revenue rising to $199.88M versus $188M a year earlier, while net loss widened to ($15.05M) and diluted EPS was ($0.46) as acquisition-related and commercial expansion costs increased — 10-Q Summary.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$199.88M$188M6.3% | Net income²($15.05M)$11.98M(225.6%) | Diluted EPS³($0.46)$0.34(235.3%) |
¹ Reported as “Product revenues, net”. ² Reported as “Net (loss) income”. ³ Reported as “earnings per share — diluted”.
Business Highlights
- Revenue growth was driven by higher volumes and pricing for Jornay PM, plus momentum from Azstarys and Belbuca.
- Authorized generic launches (Nucynta IR/ER) and Hikma generics in Feb–Mar 2026 shifted the sales mix toward AG channel sales.
- Completed the May 2026 acquisition of Azstarys and integrated its commercial sales recognition into results for the quarter.
- SG&A increased on acquisition-related expenses, executive transitions and expanded sales support for Jornay PM and Azstarys; commercialization of Belbuca and Symproic remains ongoing.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.